The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
MoFo's litigation and arbitration chair Cedric Chao and Cooley Godward biotechnology partner Bob Jones acted for Californian biopharmaceutical company Gilead Sciences in the dispute with pharmaceutical giant Roche over the licence agreement for Tamiflu.
The drug, which fights the most common influenza strains, is touted as one of the main defences against a potential bird flu pandemic.
Acting for Gilead, Jones was responsible for drawing up the original licence agreement in 1996, which saw the joint development of Tamiflu by Gilead and Roche.
But in June 2005 Gilead delivered a termination notice and the companies began arbitration. Roche instructed long-standing adviser Arthur Golden of Davis Polk & Wardwell.
The settlement provides for the joint manufacture of Tamiflu. It also eliminates a cost of goods adjustment in the payment of royalties from Roche to Gilead, and sees Roche pay Gilead $62.5m (£36.3m) in respect of adjustments made up to 2004.